Skip to main content

Table 2 EM regression output for negative-binomial, beta-binomial and Poisson

From: Migraine day frequency in migraine prevention: longitudinal modelling approaches

Negative binomial (Dispersion parameter 0.2397)

Beta-binomial (ICC 0.0297)

Poisson

Covariate

Predicted MD Frequencya

95% CI

FRR

95% CI

P value

 

Predicted MD Frequencya

95% CI

Coefficient

95% CI

P value

 

Predicted MD Frequencya

95% CI

FRR

95% CI

P value

Week 0

8.261

(7.622, 8.900)

–

–

–

Week 0

7.944

(7.334, 8.555)

–

–

–

Week 0

8.333

(7.790, 8.877)

–

–

–

Week 4

7.199

(6.714, 7.684)

0.746

(0.712, 0.782)

< 0.001

Week 4

7.081

(6.595, 7.567)

−0.292

(− 0.345, -0.239)

< 0.001

Week 4

7.312

(6.824, 7.800)

0.768

(0.737, 0.800)

< 0.001

Week 8

6.731

(6.278, 7.185)

0.693

(0.661, 0.727)

< 0.001

Week 8

6.672

(6.215, 7.128)

−0.379

(−0.433, -0.324)

< 0.001

Week 8

6.847

(6.385, 7.310)

0.718

(0.688, 0.749)

< 0.001

Week 12

6.4337

(6.005, 6.862)

0.651

(0.620, 0.683)

< 0.001

Week 12

6.386

(5.952, 6.820)

−0.447

(−0.503, -0.391)

< 0.001

Week 12

6.555

(6.108, 7.002)

0.677

(0.649, 0.706)

< 0.001

Week 24

6.421

(6.002, 6.840)

0.634

(0.604, 0.666)

< 0.001

Week 24

6.293

(5.866, 6.720)

−0.486

(−0.542, -0.429)

< 0.001

Week 24

6.552

(6.105, 6.998)

0.662

(0.634, 0.690)

< 0.001

Treatment (Erenumab vs Placebo)

0.761

(0.702, 0.825)

< 0.001

Treatment (Erenumab vs Placebo)

−0.327

(−0.362, -0.291)

< 0.001

Treatment (Erenumab vs Placebo)

0.764

(0.705, 0.827)

< 0.001

RMSE

0.075

RMSE

0.102

RMSE

0.142

MAE

0.246

MAE

0.336

MAE

0.466

  1. Regression output analysis was based on the whole sample of patients (4438 observations)
  2. CI confidence interval, FRR frequency rate ratio, ICC intraclass correlation coefficient, MAE mean absolute error, MMD monthly migraine day, RMSE root mean squared error
  3. aIn the placebo arm